ISO 15189 is a sufficient instrument to guarantee high-quality manufacture of laboratory developed tests for in-house-use conform requirements of the European In-Vitro-Diagnostics Regulation: joint opinion of task force on European regulatory affairs and working group accreditation and ISO/CEN standards of the European Federation of Clinical Chemistry and Laboratory Medicine: review
The EU In-Vitro Diagnostic Device Regulation (IVDR) aims for transparent risk-and purpose-based validation of diagnostic devices, traceability of results to uniquely identified devices, and post-market surveillance. The IVDR regulates design, manufacture and putting into use of devices, but not medi...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2023-03-28
|
| In: |
Clinical chemistry and laboratory medicine
Year: 2023, Jahrgang: 61, Heft: 4, Pages: 608-626 |
| ISSN: | 1437-4331 |
| DOI: | 10.1515/cclm-2023-0045 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1515/cclm-2023-0045 Verlag, kostenfrei, Volltext: https://www.degruyterbrill.com/document/doi/10.1515/cclm-2023-0045/html 
|
| Verfasserangaben: | Florent JLA Vanstapel, Matthias Orth, Thomas Streichert, Ettore D Capoluongo, Wytze P Oosterhuis, Hikmet Can Çubukçu, Francisco A Bernabeu-Andreu, Marc Thelen, Leo HJ Jacobs, Solveig Linko, Harjit Pal Bhattoa, Patrick MM Bossuyt, Pika Meško Brguljan, Guilaine Boursier, Christa M Cobbaert and Michael Neumaier |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1881200434 | ||
| 003 | DE-627 | ||
| 005 | 20250530002949.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240220s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/cclm-2023-0045 |2 doi | |
| 035 | |a (DE-627)1881200434 | ||
| 035 | |a (DE-599)KXP1881200434 | ||
| 035 | |a (OCoLC)1425200254 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Vanstapel, Florent |e VerfasserIn |0 (DE-588)1320986072 |0 (DE-627)1881201589 |4 aut | |
| 245 | 1 | 0 | |a ISO 15189 is a sufficient instrument to guarantee high-quality manufacture of laboratory developed tests for in-house-use conform requirements of the European In-Vitro-Diagnostics Regulation |b joint opinion of task force on European regulatory affairs and working group accreditation and ISO/CEN standards of the European Federation of Clinical Chemistry and Laboratory Medicine: review |c Florent JLA Vanstapel, Matthias Orth, Thomas Streichert, Ettore D Capoluongo, Wytze P Oosterhuis, Hikmet Can Çubukçu, Francisco A Bernabeu-Andreu, Marc Thelen, Leo HJ Jacobs, Solveig Linko, Harjit Pal Bhattoa, Patrick MM Bossuyt, Pika Meško Brguljan, Guilaine Boursier, Christa M Cobbaert and Michael Neumaier |
| 264 | 1 | |c 2023-03-28 | |
| 300 | |b Illustrationen | ||
| 300 | |a 19 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 31. Januar 2023 | ||
| 500 | |a Gesehen am 20.02.2024 | ||
| 520 | |a The EU In-Vitro Diagnostic Device Regulation (IVDR) aims for transparent risk-and purpose-based validation of diagnostic devices, traceability of results to uniquely identified devices, and post-market surveillance. The IVDR regulates design, manufacture and putting into use of devices, but not medical services using these devices. In the absence of suitable commercial devices, the laboratory can resort to laboratory-developed tests (LDT) for in-house use. Documentary obligations (IVDR Art 5.5), the performance and safety specifications of ANNEX I, and development and manufacture under an ISO 15189-equivalent quality system apply. LDTs serve specific clinical needs, often for low volume niche applications, or correspond to the translational phase of new tests and treatments, often extremely relevant for patient care. As some commercial tests may disappear with the IVDR roll-out, many will require urgent LDT replacement. The workload will also depend on which modifications to commercial tests turns them into an LDT, and on how national legislators and competent authorities (CA) will handle new competences and responsibilities. We discuss appropriate interpretation of ISO 15189 to cover IVDR requirements. Selected cases illustrate LDT implementation covering medical needs with commensurate management of risk emanating from intended use and/or design of devices. Unintended collateral damage of the IVDR comprises loss of non-profitable niche applications, increases of costs and wasted resources, and migration of innovative research to more cost-efficient environments. Taking into account local specifics, the legislative framework should reduce the burden on and associated opportunity costs for the health care system, by making diligent use of existing frameworks. | ||
| 650 | 4 | |a European Regulation 2017/746 on In-Vitro-Diagnostic Devices | |
| 650 | 4 | |a ISO 15189:2012 | |
| 650 | 4 | |a laboratory-developed tests for in-house use | |
| 650 | 4 | |a method validation | |
| 700 | 1 | |a Orth, Matthias |d 1964- |e VerfasserIn |0 (DE-588)128713704 |0 (DE-627)378310240 |0 (DE-576)167568701 |4 aut | |
| 700 | 1 | |8 1\p |a Streichert, Thomas |d 1971- |e VerfasserIn |0 (DE-588)12194123X |0 (DE-627)081635370 |0 (DE-576)293006946 |4 aut | |
| 700 | 1 | |a Capoluongo, Ettore D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Oosterhuis, Wytze P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Çubukçu, Hikmet Can |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bernabeu-Andreu, Francisco A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Thelen, Marc |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jacobs, Leo H. J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Linko, Solveig |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bhattoa, Harjit Pal |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bossuyt, Patrick M. M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brguljan, Pika Meško |e VerfasserIn |4 aut | |
| 700 | 1 | |a Boursier, Guilaine |e VerfasserIn |4 aut | |
| 700 | 1 | |8 2\p |a Cobbaert, Christa |e VerfasserIn |0 (DE-588)1283602830 |0 (DE-627)1839384824 |4 aut | |
| 700 | 1 | |a Neumaier, Michael |d 1958- |e VerfasserIn |0 (DE-588)1028284934 |0 (DE-627)730532623 |0 (DE-576)375780580 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical chemistry and laboratory medicine |d Berlin [u.a.] : De Gruyter, 1998 |g 61(2023), 4, Seite 608-626 |h Online-Ressource |w (DE-627)302923187 |w (DE-600)1492732-9 |w (DE-576)088704882 |x 1437-4331 |7 nnas |a ISO 15189 is a sufficient instrument to guarantee high-quality manufacture of laboratory developed tests for in-house-use conform requirements of the European In-Vitro-Diagnostics Regulation joint opinion of task force on European regulatory affairs and working group accreditation and ISO/CEN standards of the European Federation of Clinical Chemistry and Laboratory Medicine: review |
| 773 | 1 | 8 | |g volume:61 |g year:2023 |g number:4 |g pages:608-626 |g extent:19 |a ISO 15189 is a sufficient instrument to guarantee high-quality manufacture of laboratory developed tests for in-house-use conform requirements of the European In-Vitro-Diagnostics Regulation joint opinion of task force on European regulatory affairs and working group accreditation and ISO/CEN standards of the European Federation of Clinical Chemistry and Laboratory Medicine: review |
| 856 | 4 | 0 | |u https://doi.org/10.1515/cclm-2023-0045 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.degruyterbrill.com/document/doi/10.1515/cclm-2023-0045/html |x Verlag |z kostenfrei |3 Volltext |
| 883 | |8 1\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 2\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 951 | |a AR | ||
| 992 | |a 20240220 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 1028284934 |a Neumaier, Michael |m 1028284934:Neumaier, Michael |d 60000 |d 63300 |d 60000 |d 65200 |d 60000 |e 60000PN1028284934 |e 63300PN1028284934 |e 60000PN1028284934 |e 65200PN1028284934 |e 60000PN1028284934 |k 0/60000/ |k 1/60000/63300/ |k 0/60000/ |k 1/60000/65200/ |k 0/60000/ |p 16 |y j | ||
| 998 | |g 128713704 |a Orth, Matthias |m 128713704:Orth, Matthias |d 60000 |d 63300 |e 60000PO128713704 |e 63300PO128713704 |k 0/60000/ |k 1/60000/63300/ |p 2 | ||
| 999 | |a KXP-PPN1881200434 |e 4488202497 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Florent JLA Vanstapel, Matthias Orth, Thomas Streichert, Ettore D Capoluongo, Wytze P Oosterhuis, Hikmet Can Çubukçu, Francisco A Bernabeu-Andreu, Marc Thelen, Leo HJ Jacobs, Solveig Linko, Harjit Pal Bhattoa, Patrick MM Bossuyt, Pika Meško Brguljan, Guilaine Boursier, Christa M Cobbaert and Michael Neumaier"]},"id":{"eki":["1881200434"],"doi":["10.1515/cclm-2023-0045"]},"recId":"1881200434","physDesc":[{"noteIll":"Illustrationen","extent":"19 S."}],"origin":[{"dateIssuedKey":"2023","dateIssuedDisp":"2023-03-28"}],"person":[{"given":"Florent","role":"aut","family":"Vanstapel","display":"Vanstapel, Florent"},{"display":"Orth, Matthias","family":"Orth","role":"aut","given":"Matthias"},{"family":"Streichert","role":"aut","given":"Thomas","display":"Streichert, Thomas"},{"role":"aut","given":"Ettore D.","family":"Capoluongo","display":"Capoluongo, Ettore D."},{"family":"Oosterhuis","given":"Wytze P.","role":"aut","display":"Oosterhuis, Wytze P."},{"display":"Çubukçu, Hikmet Can","given":"Hikmet Can","role":"aut","family":"Çubukçu"},{"display":"Bernabeu-Andreu, Francisco A.","role":"aut","given":"Francisco A.","family":"Bernabeu-Andreu"},{"display":"Thelen, Marc","family":"Thelen","role":"aut","given":"Marc"},{"display":"Jacobs, Leo H. J.","role":"aut","given":"Leo H. J.","family":"Jacobs"},{"display":"Linko, Solveig","given":"Solveig","role":"aut","family":"Linko"},{"given":"Harjit Pal","role":"aut","family":"Bhattoa","display":"Bhattoa, Harjit Pal"},{"family":"Bossuyt","role":"aut","given":"Patrick M. M.","display":"Bossuyt, Patrick M. M."},{"display":"Brguljan, Pika Meško","given":"Pika Meško","role":"aut","family":"Brguljan"},{"display":"Boursier, Guilaine","role":"aut","given":"Guilaine","family":"Boursier"},{"family":"Cobbaert","given":"Christa","role":"aut","display":"Cobbaert, Christa"},{"given":"Michael","role":"aut","family":"Neumaier","display":"Neumaier, Michael"}],"relHost":[{"title":[{"title_sort":"Clinical chemistry and laboratory medicine","title":"Clinical chemistry and laboratory medicine"}],"note":["Gesehen am 22.6.2022"],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"origin":[{"publisher":"De Gruyter","dateIssuedKey":"1998","dateIssuedDisp":"1998-","publisherPlace":"Berlin [u.a.]"}],"disp":"ISO 15189 is a sufficient instrument to guarantee high-quality manufacture of laboratory developed tests for in-house-use conform requirements of the European In-Vitro-Diagnostics Regulation joint opinion of task force on European regulatory affairs and working group accreditation and ISO/CEN standards of the European Federation of Clinical Chemistry and Laboratory Medicine: reviewClinical chemistry and laboratory medicine","recId":"302923187","physDesc":[{"extent":"Online-Ressource"}],"part":{"pages":"608-626","issue":"4","text":"61(2023), 4, Seite 608-626","extent":"19","year":"2023","volume":"61"},"id":{"issn":["1437-4331"],"eki":["302923187"],"zdb":["1492732-9"],"doi":["10.1515/cclm"]},"titleAlt":[{"title":"CCLM"}],"pubHistory":["36.1998-"],"name":{"displayForm":["publ. in association with the International Federation of Clinical Chemistry and Laboratory Medicine and the Forum of the European Societies of Clinical Chemistry"]}}],"title":[{"subtitle":"joint opinion of task force on European regulatory affairs and working group accreditation and ISO/CEN standards of the European Federation of Clinical Chemistry and Laboratory Medicine: review","title":"ISO 15189 is a sufficient instrument to guarantee high-quality manufacture of laboratory developed tests for in-house-use conform requirements of the European In-Vitro-Diagnostics Regulation","title_sort":"ISO 15189 is a sufficient instrument to guarantee high-quality manufacture of laboratory developed tests for in-house-use conform requirements of the European In-Vitro-Diagnostics Regulation"}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Online veröffentlicht: 31. Januar 2023","Gesehen am 20.02.2024"]} | ||
| SRT | |a VANSTAPELFISO15189IS2023 | ||